Value in Health
June 2019 Volume 22, Issue 6, p619-750
THEMED SECTION: CURATIVE THERAPIES
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Casey Quinn, Colin Young, Jonathan Thomas, Mark Trusheim, the MIT NEWDIGS FoCUS Writing Group
p621–626 Published online: May 16, 2019
:: In total, we project that about 350 000 patients will have been treated with 30 to 60 products by 2030. About half the launches are expected to be in B-cell (CD-19) lymphomas and leukemias.
:: This should be considered against the projected prices and total treatment costs of many of these new therapies, which are expected to exceed current average acquisition costs of treatments.
:: The interplay of long-term treatment value and the upfront cell and gene therapy costs on the one hand, and access restrictions on the other hand, create a need to develop precision financing solutions that can ensure appropriate patient access to needed treatments, increase affordability for payers, and sustain private investment in innovation.